Related Experiment Video
Updated: Dec 18, 2025
11:33
Fabrication of Three-dimensional Paper-based Microfluidic Devices for Immunoassays
Published on: March 9, 2017
16.2K
Bladder cancer hunting: A microfluidic paper-based analytical device.
Qingyun Jiang1, Tingting Han1, Haijun Ren2
1School of Biomedical Engineering, Dalian University of Technology. Key Laboratory of Integrated Circuit and Biomedical Electronic System, Liaoning Province, Dalian, P. R. China.
Electrophoresis
|June 13, 2020
Summary
A new microfluidic paper-based device offers a quick and affordable way to detect bladder cancer markers in urine. This home-based test achieves high accuracy, aiding in early diagnosis and monitoring treatment response.
Area of Science:
- Biomedical Engineering
- Clinical Diagnostics
- Urology
Background:
- Bladder cancer is a growing concern, particularly among men.
- Current diagnostic methods like cystoscopy are invasive, costly, and require specialized equipment.
- There is a need for accessible, non-invasive, and cost-effective bladder cancer detection methods.
Purpose of the Study:
- To develop and validate a microfluidic paper-based analytical device (μPAD) for detecting key bladder cancer biomarkers.
- To assess the feasibility of using μPAD for rapid, home-based urine sample analysis.
- To evaluate the diagnostic efficiency of the μPAD for bladder cancer detection.
Main Methods:
- Fabrication of a novel microfluidic paper-based analytical device (μPAD).
- Detection of nuclear matrix protein 22 (NMP22) and bladder cancer antigen (BTA) in urine samples.
- Testing with urine samples from 11 bladder cancer patients and 10 healthy controls.
Main Results:
- The μPAD demonstrated a high checkout efficiency of up to 90.91%.
- The entire testing process, from sample collection to result, takes approximately 10 minutes.
- The device is suitable for convenient, home-based self-detection.
Conclusions:
- The developed μPAD offers a quick, economical, and convenient method for bladder cancer diagnosis.
- This technology facilitates early tumor detection, prognosis evaluation, and drug response monitoring.
- μPAD represents a promising advancement for accessible bladder cancer screening and management.
